CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Ruxolitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05593432
NCT05593432Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Incyte Corporation·interventional·Posted Oct 25, 2022·Updated Oct 24, 2024

In Brief

A Phase 2 clinical trial evaluating Ruxolitinib cream and Vehicle cream for Cutaneous Lichen Planus. Completed, enrolled 64 participants across 24 sites in 2 countries.

Detailed Summary

The purpose of this study will be to evaluate efficacy and safety of Ruxolitinib cream in participants With Cutaneous Lichen Planus. This is randomized, double-blind, vehicle-controlled (DBVC) study with a DBVC period of 16 weeks followed by an open label period (OLE) period of 16 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous Lichen Planus
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedOct 25, 2022
Enrollment StartNov 23, 2022
Primary CompletionOct 2, 2023
Study CompletionFeb 26, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.7 years ago

Interventions

Ruxolitinib creamdrug

Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Vehicle creamdrug

Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.